Literature DB >> 10673471

The reality of drug use in COPD: the European perspective.

M Rudolf1.   

Abstract

COPD guidelines provide advice about the appropriate use of various medications in treating patients with this condition. Comparisons of drug therapy as recommended by these guidelines with what is actually prescribed by both primary care physicians and specialist pulmonologists in a number of European countries can be examined in a variety of ways. Nonadherence to guidelines and differences between countries are caused by a number of factors, including varying degrees of misdiagnosis and different national attitudes to various classes of drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673471     DOI: 10.1378/chest.117.2_suppl.29s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

2.  Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease.

Authors:  Laetitia Huiart; Pierre Ernst; Xavier Ranouil; Samy Suissa
Journal:  Can Respir J       Date:  2006-04       Impact factor: 2.409

3.  Do symptoms predict COPD in smokers?

Authors:  Jill A Ohar; Alireza Sadeghnejad; Deborah A Meyers; James F Donohue; Eugene R Bleecker
Journal:  Chest       Date:  2010-04-02       Impact factor: 9.410

Review 4.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids.

Authors:  Shelley R Salpeter; Nicholas S Buckley
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

6.  Drug reimbursement: indicators of inappropriate resource allocation.

Authors:  Bernard Bégaud; Ulf Bergman; Hans-Georg Eichler; Hubert G M Leufkens; Peter J Meier
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

7.  Guidelines versus clinical practice in antimicrobial therapy for COPD.

Authors:  Joshua D Farkas; Harold L Manning
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

Review 8.  Health and social impacts of COPD and the problem of under-diagnosis.

Authors:  Stefano Carlone; Bruno Balbi; Michela Bezzi; Marco Brunori; Stefano Calabro; Maria Pia Foschino Barbaro; Claudio Micheletto; Salvatore Privitera; Roberto Torchio; Pietro Schino; Andrea Vianello
Journal:  Multidiscip Respir Med       Date:  2014-12-06

Review 9.  Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.

Authors:  Shelley R Salpeter
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Characteristics of prevalent and new COPD cases in Greece: the GOLDEN study.

Authors:  Eirini Mitsiki; Eleni Bania; Christos Varounis; Konstantinos I Gourgoulianis; Evangelos C Alexopoulos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.